目的 探討潔白丸聯(lián)合枸櫞酸莫沙必利片治療功能性消化不良的臨床療效。方法 回顧性分析2022年2月—2023年2月在武漢市中西醫(yī)結(jié)合醫(yī)院治療的94例功能性消化不良患者的臨床資料。根據(jù)用藥種類的不同分為對(duì)照組和治療組，每組各47例。對(duì)照組餐前口服枸櫞酸莫沙必利片，5 mg/次，3次/d；治療組在對(duì)照組治療基礎(chǔ)上餐前口服潔白丸，0.8 g/次，3次/d。兩組患者經(jīng)14 d治療。觀察兩組患者臨床療效，比較治療前后兩組患者癥狀改善時(shí)間，SID評(píng)分、NDI評(píng)分、PSQI評(píng)分和FDDQL評(píng)分，血清C反應(yīng)蛋白（CRP）、白細(xì)胞介素-6（IL-6）、白細(xì)胞介素-10（IL-10）、腫瘤壞死因子-α（TNF-α）和降鈣素基因相關(guān)肽（CGRP）水平，及胃腸激素指標(biāo)胃動(dòng)素（MTL）、胃蛋白酶原Ⅰ（PGI）、胃蛋白酶原Ⅱ（PGII）和胃泌素（GAS）水平。結(jié)果 治療后，治療組臨床有效率（97.87%）明顯高于對(duì)照組（80.85%，P＜0.05）。治療后，治療組癥狀改善時(shí)間均明顯早于對(duì)照組（P＜0.05）。治療后，兩組患者SID評(píng)分明顯降低，而NDI評(píng)分、PSQI評(píng)分和FDDQL評(píng)分均較治療前顯著升高（P＜0.05），且治療組評(píng)分改善程度比對(duì)照組更顯著（P＜0.05）。治療后，兩組血清CRP、IL-6、IL-10和TNF-α水平明顯降低，而CGRP、MTL、PGI、PGII和GAS水平明顯升高（P＜0.05），且治療組明顯好于對(duì)照組（P＜0.05）。結(jié)論 潔白丸聯(lián)合枸櫞酸莫沙必利片治療功能性消化不良可有效改善臨床癥狀，降低機(jī)體炎癥反應(yīng)，促進(jìn)胃腸動(dòng)力，促進(jìn)患者生活質(zhì)量及睡眠質(zhì)量提高。

Objective To explore the clinical efficacy of Jiebai Pills combined with Mosapride Citrate Tablets in treatment of functional dyspepsia. Methods The clinical data of patients (94 cases) with functional dyspepsia in Wuhan Hospital of Traditional Chinese and Western Medicine from February 2022 to February 2023 were analyzed retrospectively. They were randomly divided into control and treatment group, and each group had 47 cases. Patients in the control group were po administered with Mosapride Citrate Tablets before meal, 5 mg/time, three times daily. Patients in the treatment group were po administered with Jiebai Pills on the basis of the control group, 0.8 g/time, three times daily. Patients in two groups were treated for 14 d. After treatment, the clinical evaluation was evaluated, and the improvement time of symptom, the scores of SID, NDI, PSQI and FDDQL, the levels of CRP, IL-6, IL-10, TNF-α and CGRP, and the levels of gastrointestinal hormone indicators MTL, PGI, PGII and GAS in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group (97.87%) was significantly higher than that of the control group (80.85%, P < 0.05). After treatment, the improvement time of symptom in the treatment group was significantly earlier than that in the control group (P < 0.05). After treatment, the SID score was significantly decreased, while the NDI score, PSQI score and FDDQL score were significantly increased in two groups (P < 0.05), and the improvement of score in the treatment group was more significant than that in the control group (P < 0.05). After treatment, the serum levels of CRP, IL-6, IL-10 and TNF-α were significantly decreased, while the levels of CGRP, MTL, PGI, PGII and GAS were significantly increased in two groups (P < 0.05), and these indicators in the treatment group was significantly better than those in the control group (P < 0.05). Conclusion Jiebai Pills combined with Mosapride Citrate Tablets in treatment of functional dyspepsia can effectively improve clinical symptoms, reduce inflammatory reaction, promote gastrointestinal motility, and improve the quality of life and sleep of patients.

R975

湖北省衛(wèi)生健康委員會(huì)科研項(xiàng)目立項(xiàng)合同書（UJ2019F037）